帝王国际投资2026年年报

Contents目 錄 Corporate Information2Management Discussion and Analysis5Biographical Details of Directors and Senior Management43Directors’ Report48Corporate Governance Report65Independent Auditor’s Report106Consolidated Statement of Profit or Loss andOther Comprehensive Income115Consolidated Statement of Financial Position117Consolidated Statement of Changes in Equity119Consolidated Statement of Cash Flows120Notes to the Consolidated Financial Statements122Five Year Financial Summary192 King InternationalInvestmentLimitedA nnual Repor t2026 Corporate I n f o r m ation公 司 資 料 EXECUTIVE DIRECTORS Mr. Leng Yueyingtan(Co-Chairman) (appointed on 20 December 2024and redesignated as Co-chairman on 4 December 2025) Wang Jun(Co-Chairman) (appointed on 4 December 2025) Mr. Wang MengyaoMr. Man Wai LunMr. Li Li (appointed on 19 September 2024, re-designated asNon-Executive Director on 6 January 2025 and redesignated asExecutive Director on 13 June 2025) Ms. Yan Ming (appointed as Independent Non-Executive Director on 23August 2023, re-designated as Executive Director on 19 March 2024,suspended on 24 April 2025 and removed on 9 January 2026) INDEPENDENT NON-EXECUTIVE DIRECTORS Mr. Lou TaoMr. Liu ZhongMr. Li Qian (appointed on 24 April 2026) Ms. Yang Xilin (resigned on 10 April 2025)Mr. Wang Zhenyu (removed on 9 January 2026) AUDIT COMMITTEE Mr. Li Qian(Chairman) (appointed on 24 April 2026) Mr. Leng YueyingtanMr. Liu Zhong REMUNERATION COMMITTEE Mr. Liu Zhong(Chairman) (appointed on 10 April 2025) Mr. Leng YueyingtanMs. Li Qian (appointed on 24 April 2026) Ms. Yang Xilin (resigned on 10 April 2025) NOMINATION COMMITTEE Mr. Leng Yueyingtan(Chairman) (appointed on 6 January 2025) Mr. Man Wai LunMs. Li Qian (appointed on 24 April 2026) Ms. Yang Xilin (resigned on 10 April 2025) AUTHORISED REPRESENTATIVESMr. Wang MengyaoMr. Wong Ka Sing COMPANY SECRETARYMr. Wong Ka Sing 38223 AUDITOR ZHONGHUI ANDA CPA Limited23/F, Tower 2, Enterprise Square Five38 Wang Chiu RoadKowloon Bay, KowloonHong Kong PRINCIPAL BANKERBank of Communications (Hong Kong) Limited Cricket Square, Hutchins DriveP.O. Box 2681Grand Cayman KY1-1111Cayman Islands REGISTERED OFFICECricket Square, Hutchins DriveP.O. Box 2681Grand Cayman KY1-1111Cayman Islands 15111101 PRINCIPAL OFFICE IN HONG KONG 1101, 11th Floor,Gloucester Tower, The Landmark,15 Queen’s Road Central,Hong Kong King International Investment LimitedA nnual Repor t2026 Corporate I n f o r m ation公 司 資 料 www.kinginternational.hk COMPANY’S WEBSITEwww.kinginternational.hk CAYMAN ISLANDS PRINCIPAL SHAREREGISTRAR AND TRANSFER OFFICE Suntera (Cayman) LimitedCricket SquareHutchins DriveP.O. Box 2681Grand CaymanKY1-1111Cayman Islands Suntera (Cayman) LimitedCricket SquareHutchins DriveP.O. Box 2681Grand CaymanKY1-1111Cayman Islands HONG KONG BRANCH SHARE REGISTRARAND TRANSFER OFFICE 1617 Tricor Investor Services Limited17/F, Far East Finance Centre16 Harcourt RoadHong Kong 00928 LISTING INFORMATIONThe Stock Exchange of Hong Kong LimitedStock Code: 00928 Management Discussion and Analysis管 理 層 討 論 及 分 析 On behalf of King International Investment Limited (the “Company”),I present to the shareholders the results of the Company and itssubsidiaries (collectively referred to as the “Group”) for the year ended31 March 2026. OVERVIEW The Company is an investment holding company. The Company and itssubsidiaries (the “Group”) are principally engaged in healthcare productsand services business and sales of liquor Business. On one hand, the Company, through its subsidiaries, provides medicalsupplies including medical thermometers, masks, protective clothing,disinfectant, virus testing kits and reagents, breathing machines and othermedical products, and also provides value-added services in respectof the procurement of such medical supplies and products includingproviding market intelligence, sourcing of bids, comparative assessmentof technical specifications and cost analysis, and negotiation of terms ofsupply. The Group continued to developing domestic healthcare equipmentser vice business. Taking advantage of its own advantages, the Groupintegrates health data analysis software and healthcare equipment toprovide new healthcare services and products business, which has beenrecognized by the industry. The Group also expands its business totrading of hygiene products to ride on the demand for personal andhousehold hygiene due to the growing awareness among consumers inthe wake of the COVID-19 pandemic. Following the deconsolidation ofcertain subsidiaries, the Company shifted its business to Hainan LuckyLight Brand Management Co., Ltd.to operate the healthcare business. The Company has been tradingdisinfectant water since April 1, 2025, which has contributed considerablerevenue to the healthcare segment. The Company believes that thetrading of disinfectant water will continue to grow and will become asignificant component of the healthcare segment. Manageme n t D i s c u